Back to Search
Start Over
HCC recurrence in HCV‐infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post‐hoc analysis
- Source :
- Transplant International. 33:917-924
- Publication Year :
- 2020
- Publisher :
- Frontiers Media SA, 2020.
-
Abstract
- Factors affecting outcomes in liver transplant (LTx) recipients with hepatocellular carcinoma (HCC) and hepatitis C viral (HCV) infection include the choice of immunosuppression. Here, we analyzed the HCV+ subgroup of patients from the randomized controlled, international SiLVER Study. We performed a post hoc analysis of 166 HCV+ SiLVER Study patients regarding HCC outcome after LTx. Control patients (group A: n=88) received mTOR inhibitor (mTORi)-free, calcineurin inhibitor (CNI)-based versus sirolimus-based immunosuppression (group B: n=78). We found no significant difference regarding HCV-RNA titers between group A and B. Since no effect in group B could be due to variable sirolimus dosing, we split group B into patients receiving sirolimus-based immunosuppression+CNIs for >50% (B1; n=44) or
- Subjects :
- Silver Study
medicine.medical_specialty
Carcinoma, Hepatocellular
Silver
direct-acting antiviral agents
medicine.medical_treatment
610 Medizin
Subgroup analysis
030230 surgery
Liver transplantation
Gastroenterology
Group B
03 medical and health sciences
HEPATOCELLULAR-CARCINOMA
hepatitis C virus infection
hepatocellular carcinoma
liver transplantation
0302 clinical medicine
Internal medicine
Post-hoc analysis
medicine
Humans
Sirolimus
direct-acting antiviral agent
ddc:610
Transplantation
business.industry
Liver Neoplasms
Immunosuppression
medicine.disease
Hepatitis C
digestive system diseases
Calcineurin
Hepatocellular carcinoma
030211 gastroenterology & hepatology
Neoplasm Recurrence, Local
business
medicine.drug
Subjects
Details
- ISSN :
- 14322277 and 09340874
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Transplant International
- Accession number :
- edsair.doi.dedup.....d92e9a6688afdd3f94d136c4cfed0e6f